Barclays
BCRX icon

Barclays’s BioCryst Pharmaceuticals BCRX Stock Holding History

Barclays’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$75.2K – 5270
2024
Q4 		$75.2K Hold
10,000
– – ﹤0.01% 4654
2024
Q3 		$76K Buy
+10,000
New +$76K ﹤0.01% 4642
2024
Q2 		– Sell
-20,000
Closed -$102K – 4880
2024
Q1 		$102K Sell
20,000
-40,000
-67% -$225K ﹤0.01% 4429
2023
Q4 		$359K Buy
+60,000
New +$348K ﹤0.01% 4091
2019
Q3 		– Sell
-211,500
Closed -$802K – 6711
2019
Q2 		$802K Buy
211,500
+101,300
+92% +$610K ﹤0.01% 3911
2019
Q1 		$897K Buy
110,200
+95,900
+671% +$821K ﹤0.01% 3519
2018
Q4 		$115K Sell
14,300
-6,400
-31% -$49.8K ﹤0.01% 4942
2018
Q3 		$158K Buy
20,700
+14,200
+218% +$95.4K ﹤0.01% 5183
2018
Q2 		$37K Sell
6,500
-800
-11% -$4.4K ﹤0.01% 5823
2018
Q1 		$35K Sell
7,300
-14,600
-67% -$75K ﹤0.01% 6142
2017
Q4 		$108K Sell
21,900
-2,800
-11% -$13.6K ﹤0.01% 5178
2017
Q3 		$129K Buy
24,700
+5,700
+30% +$29.2K ﹤0.01% 4752
2017
Q2 		$106K Buy
19,000
+10,400
+121% +$63.3K ﹤0.01% 4854
2017
Q1 		$72K Buy
8,600
+6,700
+353% +$46.6K ﹤0.01% 5110
2016
Q4 		$12K Sell
1,900
-14,600
-88% -$76K ﹤0.01% 5824
2016
Q3 		$73K Buy
16,500
+15,200
+1,169% +$60.7K ﹤0.01% 4731
2016
Q2 		$4K Sell
1,300
-1,800
-58% -$5.59K ﹤0.01% 5777
2016
Q1 		$6K Sell
3,100
-14,200
-82% -$62.9K ﹤0.01% 5613
2015
Q4 		$173K Buy
17,300
+10,200
+144% +$101K ﹤0.01% 4017
2015
Q3 		$78K Sell
7,100
-1,200
-14% -$16K ﹤0.01% 4765
2015
Q2 		$116K Sell
8,300
-6,900
-45% -$78.4K ﹤0.01% 4564
2015
Q1 		$137K Sell
15,200
-4,300
-22% -$44.5K ﹤0.01% 4625
2014
Q4 		$234K Sell
19,500
-100
-0.5% -$1.1K ﹤0.01% 4516
2014
Q3 		$176K Sell
19,600
-3,100
-14% -$38K ﹤0.01% 4850
2014
Q2 		$272K Buy
22,700
+1,100
+5% +$10.7K ﹤0.01% 4521
2014
Q1 		$216K Buy
21,600
+17,700
+454% +$189K ﹤0.01% 4712
2013
Q4 		$27K Sell
3,900
-86,700
-96% -$549K ﹤0.01% 6544
2013
Q3 		$634K Buy
90,600
+88,000
+3,385% +$446K ﹤0.01% 3849
2013
Q2 		$4K Buy
+2,600
New +$4.49K ﹤0.01% 7395

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Barclays's BCRX Position: Q1 2026 in Review

Barclays reduced its BioCryst Pharmaceuticals (BCRX) stake by 82% in Q1 2026, selling an estimated $4.6M and leaving 133,597 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Barclays first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.2M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Barclays held 133,597 shares of BioCryst Pharmaceuticals worth $1.27M as of Q1 2026.
  • Barclays sold 592,770 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $4.6M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2601 holding.
  • Barclays first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's BioCryst Pharmaceuticals position peaked at $7.2M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.